Abstract 746P
Background
In the primary analysis of the MIRASOL trial, MIRV demonstrated superior progression-free survival (PFS), objective response rate, and overall survival (OS), over ICC in patients (pts) with high-grade serous PROC (Moore K et al. N Engl J Med 2023;389:2162-74) with a median follow-up time of 11.2 months. Here, we report updated nonanalytical results based on a median follow-up of 16.7 months.
Methods
453 PROC pts with high FRα expression (VENTANA FOLR1 [FOLR1-2.1] RxDx Assay) with 1-3 prior therapies were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day 1 of a 21-day cycle or ICC: paclitaxel (PAC), pegylated liposomal doxorubicin (PLD), or topotecan (Topo). The primary efficacy endpoint was PFS by an investigator, with key secondary endpoints ORR, OS, and patient-reported outcomes in hierarchical order; other endpoints included safety, tolerability, and duration of response.
Results
With an extended data cutoff of October 27, 2023, the mPFS was 5.6 months (95% CI 4.3, 6.0) for MIRV vs 4.0 months (95% CI 2.9, 4.5) for ICC with a hazard ratio (HR) of 0.65 (95% CI 0.53, 0.80). The mOS was 16.5 months (95% CI 14.4, 19.9) for MIRV and 13.3 months (95% CI 11.4, 15.4) for ICC with a HR of 0.67 (95% CI 0.53, 0.85). The adverse event (AE) profile of MIRV was consistent with prior reports and included: blurred vision (MIRV 43% vs ICC 2%; grade 3+ 8% vs 0), keratopathy (MIRV 33% vs. ICC 0; grade 3+ 9% vs 0), abdominal pain (MIRV 31% vs ICC 15%; grade 3+ 3% vs 1%), fatigue (MIRV 30% vs ICC 25%; grade 3+ 2% vs 5%), diarrhea (MIRV 29% vs ICC 17%; grade 3+ 1% vs <1%). Compared with ICC, MIRV was associated with lower rates of grade 3+ treatment-emergent AEs (43% vs. 54%), serious AEs (25% vs. 33%), and discontinuations due to TEAEs (10% vs. 16%). 5% of pts on the MIRV arm remained on study drug vs <1% on the IC arm.
Conclusions
With a median follow-up of 16.7 months, MIRV demonstrated improved efficacy vs ICC in pts with PROC. The efficacy data, along with the well-characterized safety profile, supports MIRV as the standard of care for pts with FRα positive PROC. Clinical Trial Information: NCT04209855.
Clinical trial identification
NCT04209855.
Editorial acknowledgement
Legal entity responsible for the study
ImmunoGen, Inc.
Funding
ImmunoGen, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01